AOD-9604


Modified hGH 176-191 fragment

A modified C-terminal fragment of hGH (residues 176-191) developed for fat loss without GH metabolic effects.

Abstract

AOD-9604 (modified hGH 177-191; molecular formula C78H125N23O23S2) is a modified analog of the C-terminal fragment of human growth hormone (residues 176-191) developed by Monash University and Metabolic Pharmaceuticals. The structural modification is the addition of a tyrosine at the N-terminus relative to the unmodified 176-191 sequence. The compound was developed on the rationale that the lipolytic activity of human growth hormone resides in the C-terminal fragment, separable from the IGF-1-mediated growth-promoting and pro-diabetogenic activities. Phase 2 trials in obesity showed modest weight loss and fat mass reduction without effect on lean mass or insulin sensitivity. The compound did not advance to FDA approval; clinical efficacy was not strong enough to support marketing. The compound is sold as a research chemical/peptide.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph